TheraRadar
Data updated: May 26, 2026

DICLEGIS (doxylamine succinate)

Gastrointestinal Approved 2013-04-08

Diclegis is a combination medication that helps pregnant women manage nausea and vomiting when conservative treatments are not effective. It combines two active ingredients: doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a Vitamin B6 analog. This treatment is specifically for those who do not respond to initial lifestyle or dietary changes, though it has not been studied for use in cases of hyperemesis gravidarum.

Source: FDA Label • DUCHESNAY

How DICLEGIS Works

The specific mechanism by which this medication works to alleviate symptoms is unknown. It functions as a fixed-dose combination of an antihistamine and a Vitamin B6 analog.

1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Prescription
First Approved
2013-04-08
Routes
ORAL
Dosage Forms
TABLET, DELAYED RELEASE

Companies

DICLEGIS Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
12 FDA actions from 2013 to 2022
Oct 2022 SUPPL
Label · Labeling
Jun 2018 SUPPL
Label · Labeling
Mar 2016 SUPPL
Mfg · Manufacturing (CMC)

What DICLEGIS Treats

1 indications

DICLEGIS is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Nausea and Vomiting of Pregnancy
Source: FDA Label

DICLEGIS Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DICLEGIS

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

BONJESTA
DOXYLAMINE SUCCINATE
1 shared
DUCHESNAY
Shared indications:
Nausea and Vomiting of Pregnancy
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE
1 shared
BIONPHARMA
Shared indications:
Nausea and Vomiting of Pregnancy
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT02045901 PED-301 PED-301 Ph 4 terminated A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DICLEGIS FDA Label Details

Indications & Usage

FDA Label (PDF)

DICLEGIS is indicated for the treatment of Nausea and Vomiting of Pregnancy.

Track DICLEGIS with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.